Galunisertib is a potent small-molecule TGF-β receptor type I (TGF-βR1) kinase inhibitor. It selectively inhibits TGF-βR1 kinase activity, blocking SMAD2/3 phosphorylation and downstream TGF-β/Smad signaling. It shows significant therapeutic value in oncology, fibrosis, and immuno-oncology.
Galunisertib (LY2157299) IC50 for Cell-based and Cell-free Assays
Comprehensive lC50 Values for Galunisertib (LY2157299) Across Cell-free Enzyme Inhibitory Profiles and Cell- based Functional Assays.